The firms’ Orserdu has won a US thumbs up for the treatment of ESR1-mutated advanced or metastatic breast cancer, marking a positive breakthrough for the challenging SERD drug class.

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Drug makers have sought to branch into new frontiers of drug development in areas like cancers and neurology, but not all of them have been success stories. Here, Scrip looks at some of the more notable clinical trial misses of last year.

Several factors differentiate Olema Oncology’s lead drug candidate from the SERD herd, says its CEO Sean Bohen, as the firm looks to partner the ‘ready-for-Phase III multibillion-dollar asset.’